What is RetiSpec?
RetiSpec Inc. is a pioneering medical imaging company focused on the early detection of Alzheimer's disease biomarkers within the eye. Leveraging advanced machine learning, RetiSpec's non-invasive, simple, and cost-effective diagnostic tool aims to make widespread screening for Alzheimer's pathology accessible. The company's mission is to enable earlier intervention and management of the disease, addressing a critical unmet need in neurological healthcare. Based in Toronto, RetiSpec is actively involved in prominent innovation networks such as the Ontario Brain Institute (OBI) and the Centre for Aging and Brain Health Innovation (CABHI), highlighting its commitment to advancing brain health research and technology.
How much funding has RetiSpec raised?
RetiSpec has raised a total of $10M across 1 funding round:
Series A
$10M
Series A (2024): $10M with participation from Lilly, Topcon Healthcare, and iGan Partners
Key Investors in RetiSpec
Lilly
Eli Lilly and Company is a global biopharmaceutical firm engaged in the discovery, development, manufacturing, and commercialization of prescription medicines. It focuses on areas such as diabetes, oncology, immunology, and neuroscience, serving patients across international markets through research-driven innovation.
Topcon Healthcare
Topcon Healthcare, part of Topcon Corporation, is a global technology manufacturer focused on advanced optical and digital solutions for the healthcare industry. They specialize in creating innovative technologies for disease detection, monitoring, and management, aiming to improve patient care through precision optics and digital insights.
iGan Partners
iGan Partners is a leading Canadian venture capital firm specializing in healthcare investments across North America. They provide smart capital and strategic support to innovative healthcare companies, partnering with founders to commercialize and scale disruptive solutions within the healthcare sector.
What's next for RetiSpec?
The substantial enterprise-level funding secured by RetiSpec signals a pivotal moment for the company, likely enabling an acceleration of its product development, clinical validation, and market penetration strategies. This capital infusion is expected to fuel the scaling of its operations, potentially expanding its research and development capabilities and forging strategic partnerships to broaden the reach of its diagnostic technology. RetiSpec's focus on early Alzheimer's detection positions it to capture a significant share of the growing neurodegenerative disease diagnostics market, with future growth contingent on successful clinical trials and regulatory approvals.
See full RetiSpec company page
